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We report the use of high dose chemotherapy with peripheral blood stem cell rescue as a consolidation treatment
for a 3-year-old child affected by metastatic hepatoblastoma, who achieved complete lung response only after
conventional treatment. The patient is presently alive 27 months after high dose chemotherapy with blood stem
cell rescue with no evidence of disease.
The role of high dose chemotherapy with blood stem cell rescue to consolidate the complete clearing of lung
disease in metastatic hepatoblastoma remains controversial; the data available in the literature and our experience
seems to suggest to keep this treatment option open to further consideration in the clinical setting of high-risk
patients.Background
Hepatoblastoma (HB) is the most common malignant
liver tumor in children. Current multidrug chemotherapy
regimens and surgery allow to obtain event free survival
(EFS) and overall survival (OS) rates of approximately 70-80%
[1-4]. However, the outcome of children with metastatic
tumor remains unsatisfactory, with EFS and OS of 25-38%
and 27-62% range respectively [2-11]. Intensification of con-
ventional chemotherapy, notably with cisplatin (CDDP),
and the use of innovative combinations of drugs in a “win-
dow setting”, and more precisely, irinotecan and vincristine,
are the two strategies adopted respectively by the European
and North American cooperative study groups on HB to
improve the present treatment outcome on these latter pa-
tients [2,12].
In the literature the use of high dose chemotherapy
(HDCT) with blood stem cell (BSC) rescue has been
reported in children affected by metastatic HB in 21 cases.
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reproduction in any medium, provided the orthis subject and our personal observation may serve to
provide a more comprehensive understanding of the
role of this therapeutic approach in children with HB
and high-risk features of treatment failure, notably me-
tastases, and potentially to support further stringent
clinical investigation.Case presentation
A three-year-old boy was referred to our center because
of an asymptomatic abdominal mass. At the time of
diagnosis, the alpha-feto protein (AFP) serum level was
192,269 ng/mL (normal value < 10 ng/mL) and the
platelet count 486,000/mcl. The abdominal computed
tomography (CT) showed an intrinsic hepatic tumor mass
involving extensively the right hepatic lobe (segment VI,
VII and VIII). The mass was classified as PRETEXT II
(tumor volume: 13×12×10 cm) [13]. The surgical biopsy
was in favor of an epithelial HB. The chest CT scan
showed bilateral widespread metastatic lung disease. After
obtaining informed consent, the patient was treated
according to SIOPEL 4 protocol with CDDP 70 mg/sqm
as a 24-hour continuous infusion (CI) on day 1, 7, and
14 (first dose of the first block CDDP at 80 mg/sqm as al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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48-hour CI on day 8 and 9; this block had to be repeated
three times (omitting last CDDP) at one week interval.
The abdominal CT scan performed thereafter exhibited
a reduction of the extension of the hepatic mass
(7.5×5.1×4.5 cm), now involving only segment VII and
VIII, while the chest CT scan showed only a partial
response (PR) of the lung lesions, which remained bilateral
and widespread. The AFP level decreased to 588 ng/ml.
The surgical resection of the lung lesions was not
performed because of the multifocality and the bilaterality
of the disease. The patient underwent right hepatectomy
and the histology was refined as a fetal HB with a rich
macrotrabecular component (80% of the mass). The micro-
scopic margins were clear. The AFP value further declined
to 44.3 ng/ml 13 days after surgery. Post-surgery chemo-
therapy consisted of carboplatin (CARBO) 500 mg/sqm on
day 1, 22 and 43, and DOXO 20 mg/sqm as a 24-hour CI
on day 1, 2, 22, 23, 43, and 44. At the end of the treatment
the AFP returned to normal (7.7 ng/ml) and the chest
CT scan revealed no signs of residual lung disease.
Fearing that the late response of the metastases (i.e. at
least a partial response to preoperative chemotherapy
and complete remission of pulmonary metastases only
after postoperative chemotherapy, regardless AFP levels)
could be a dismal prognostic factor it was elected, with
parental agreement, to complete therapy with a course
of HDCT and peripheral BSC rescue. Autologous BSC
were harvested in 2 days (total 1.3 × 106 and 3 × 106
CD34+ cells/kg), after G-CSF stimulation. As used in
our center for other metastatic solid tumors, the conditio-
ning regimen consisted of CARBO 500 mg/sqm/die from
day −5 to day −3; etoposide 300 mg/sqm/die from day −5
to day −3; melphalan 120 mg/sqm/die on day −2. On day
0 and day +1 BSC (3 × 106 and 1.3 × 106 CD34+ cells/kg)
were infused. From day +4 to day +14 G-CSF was given;
neutrophil count was over 500/mm3 since day +12 while
platelet engraftment (>20000/mcl, transfusion independ-
ent) was documented from day +13. Toxicity was modest
and represented by mucositis and fever of unknownTable 1 High dose chemotherapy with blood stem cell rescue
HB patients achieving partial response after pre-operative ch
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marrow.origin. Presently the patient remains disease-free, with
normal AFP levels and no radiological evidence of disease,
27 months following HDCT with peripheral BSC rescue.
Summary of the literature
The use of HDCT with BSC rescue has been used in a
number of patients with HB at the time of tumor recur-
rence [10,14-18], but in only 22 of them, including the
one here reported, as a first line treatment in patients
with metastatic disease [14,15,19,20]. These 22 patients
represent the focus of this report. In 2 of them a double
autologous BSC rescue instead of conventional post-
operative chemotherapy was performed; one of these
underwent BSC rescue with persisting lung involve-
ment. Both patients relapsed, but interestingly one of
them was then rescued with irinotecan alone [14]. Four-
teen patients did not achieve PR of the target lesions
after conventional pre-operative chemotherapy (POC)
and without further specifications regarding the tumor
status at the time of HDCT all were then treated with
HDCT with BSC rescue. Of these patients 2 died of
toxicity of the procedure and only 4 were reported alive
with no evidence of disease [20].
The last subgroup of children of whom we have detailed
information encompasses 6 patients who achieved at least
a PR after POC, and after conventional partial hepatec-
tomy and post-operative chemotherapy underwent HDCT
with BSC rescue, while in complete remission (CR) of lung
metastases (see Table 1).
In these group of children four of them obtained
complete clearance of metastases with POC but
presented with persisting high serum levels of AFP after
post-operative chemotherapy; three of these four patients
at the time of the report were alive and disease-free
16 months after BSC rescue, with normal AFP levels,
while one displayed continuously increasing AFP and
ultimately died of brain metastases [19]. One case pre-
senting with multiple metastatic disease that completely
responded to POC is reported alive and disease-free six
years from stopping therapy [15]. Our patient was a latefollowing post-operative chemotherapy for metastatic
emotherapy







FP↑ CARBO, VP16, MLP PB 3 NED 16 mts after
BSC rescue 1 DoD
ED DOXO, VP16,
CARBO, 5-FU
BM NED 6 yr after BSC
rescue
ED CARBO, VP16, MLP PB NED 27 mts after
BSC rescue
HP-adriamicin, AFP alpha-feto protein, CARBO carboplatin, VP16 etoposide,
died of disease, yr years, DOXO doxorubicin, 5-FU 5 fluorouracil, BM bone
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is alive with no evidence of disease 27 months after BSC
rescue. Thus as overall five of these 6 patients had been
reported to be alive with no evidence of disease with a
minimum follow-up of 16 months after BSC rescue.
This small series of twenty-two patients cannot provide
a comprehensive view of the role of HDCT with BSC res-
cue in the treatment of HB. However, the fact that 5 out
of the 6 children achieved at least a PR after conventional
POC and received HDCT with autologous BSC rescue
while in CR of lung metastases at the end of conventional
treatment seems to indicate a possible role of this treat-
ment modality in the management of these patients.
Conclusions
The experiences here reported may suggest thus that
HDCT with autologous BSC rescue can be of benefit for
patients with metastatic HB who achieved at least a PR
after POC, as a consolidation of a CR of lung metastases
otherwise achieved at the end of treatment. Moreover
HDCT and BSC rescue can be feasible in patients who
have already received intensive conventional chemothe-
rapy but the underlying possible severe toxicity of this
modality should be clearly kept in mind and parents
should be closely involved in the decision process. Of
course nobody knows if in these children the previous
treatment, which allowed them to achieve the complete
tumor response, would have been enough for the cure.
However, considering that late response to chemothe-
rapy is indeed a matter of concern in all tumor types, to
have presented the series herewith reported could serve
to keep the treatment option of using HDCT with BSC
rescue of children affected by metastatic HB open to
further clinical investigation.
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